Similar to FGF-2, IL-6, MCP-3 and GRO were increased in supernatants of GIST T-1R treated with IM or siRNA KIT, thereby revealing the functional relationship between secretory phenotype and the inhibition of KIT-signaling (Figure 1E). This evidence concerns the gene FGF2 and gastrointestinal stromal tumor.